This is the text extract for 2011-07 Schedule Dispatch, browse documents here.

---

Available at www.pharmac.govt.nz/scheduledispatch

16 June 2011 July 2011 Pharmaceutical Schedule Dispatch (4 pages) This document is provided to pharmacists as an early notification of the changes to be announced in the July 2011 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details. SYMBICORT AND OXIS CLARIFICATION Due to the recent subsidy changes for Oxis and Symbicort Turbuhaler (all strengths) an endorsement now applies from 1 July 2011. Our intention is to ensure that all current patients who have received a subsidised prescription or who have been dispensed Symbicort or Oxis prior to the 1st of July 2011 remain fully funded. This measure will be in place while PHARMAC takes time to consider options for managing subsidies for these medicines on an ongoing basis. Patients who have had prior Special Authority approvals and dispensing before 1 July 2011 will be entitled to full subsidy as long as the prescription is endorsed by the pharmacist or the doctor. o If a patient has a subsidised prescription that was initiated prior to 1 July 2011, the repeats are fully subsidised. For those patients who have had prior subsidised dispensing to 1 July 2011 and who have a current Special Authority (Symbicort only) and present with a new prescription for Oxis or Symbicort after 1 July 2011 the pharmacist may annotate the prescription to indicate the patient has had prior dispensings of (Oxis or Symbicort). For new patients to your pharmacy that have had Symbicort and/or Oxis dispensed fully subsidised prior to 1 July 2011 the pharmacist must contact the prescriber or previous pharmacy to verify prescribing history. A record of this must be kept electronically on the patients file and the script must be annotated accordingly. Patients with a new Special Authority number (Symbicort only) and a prescription for Symbicort and/or Oxis dated before 1 July will be entitled to fully subsidy with endorsement, even if the prescription is presented to the pharmacy after 1 July 2011 Patients who have no history of either Oxis or Symbicort (i.e. new patients) and who have a prescription dated after 1 July 2011 will only be entitled to the partially subsidy and a part charge will apply. Patients will still require a valid Special Authority approval to access the partial subsidy.

o

o

o

o

New listings  Clindamycin (Dalacin C) inj phosphate 150 mg per ml, 4 ml, 10 inj pack – Retail pharmacy – Specialist (p’code 2387131)  Dabigatran (Pradaxa) cap 75 mg (p’code 2319586), 110 mg (p’code 2377578) and 150 mg (p’code 2377551), 60 cap OP’s – will not be funded Close Control in amounts less than 4 weeks of treatment – cap 75 mg no more than 2 cap per day  Fludarabine phosphate (Fludarabine Ebewe) inj 50 mg – PCT only – Specialist (p’code 2386933)  Mycophenolate mofetil (Ceptolate) cap 250 mg (p’code 2380382) and tab 500 mg (p’code 2380390) – Special Authority – Retail pharmacy  Nicotine (Habitrol) gum 384 piece pack – up to 384 pieces of gum available on a PSO – nicotine will not be funded Close Control in amounts less than 4 weeks of treatment o Gum 2 mg (classic) (p’code 2385333)

A431188

---

Available at www.pharmac.govt.nz/scheduledispatch

      

o Gum 2 mg (fruit) (p’code 2381354) o Gum 2 mg (mint) (p’code 2381346) o Gum 4 mg (classic) (p’code 2385341) o Gum 4 mg (fruit) (p’code 2381338) o Gum 4 mg (mint) (p’code 2381311) Olanzapine pamoate monohydrate (Zyprexa Relprevv) inj 210 mg (p’code 2337339), 300 mg (p’code 2337347) and 405 mg (p’code 2337355) – Special Authority – Retail pharmacy Omeprazole (Midwest) powder 5 g – only in combination – only in extemporaneously compounded omeprazole suspension (p’code 2387085) Paracetamol with codeine (Relieve) tab paracetamol 500 mg with codeine phosphate 8 mg (p’code 2383454) Permethrin (Lyderm) crm 5%, 30 g OP (p’code 479233) Pyridoxine hydrochloride (PyridoxADE) tab 25 mg – no more than 100 mg per dose – only on a prescription - no patient co-payment payable (p’code 2386372) Raloxifene hydrochloride (Evista) tab 60 mg – Special Authority – Retail pharmacy (p’code 237523) Teriparatide (Forteo) inj 250 μg per ml, 2.4 ml – Special Authority – Retail pharmacy (p’code 2222906)

Changes to restrictions  Alendronate sodium (Fosamax) tab 70 mg – amended Special Authority criteria  Alendronate sodium with cholecalciferol (Fosamax Plus) tab 70 mg with cholecalciferol 5, 600 iu – amended Special Authority criteria  Budesonide with eformoterol (Symbicort Turbuhaler) all presentations – higher subsidy with endorsement  Docetaxel (Docetaxel Ebewe, Taxotere and Baxter) inj 20 mg, inj 80 mg and inj 1 mg for ECP – removal of Special Authority  Eformoterol fumarate (Oxis Turbuhaler) powder for inhalation, 6 μg per dose, breath activated – higher subsidy with endorsement  Fluconazole (Pacific) cap 150 mg – amended endorsement  Lignocaine hydrochloride (Xylocaine Viscous) viscous soln 2% – amended presentation description  Nictoine (Habitrol) all strengths of patches, lozenge and gum – available on PSO  Omeprazole suspension – change to Standard Formulae  Vancomycin hydrochloride (Mylan) inj 500 mg – amended presentation description and brand name change  Varenicline tartrate (Champix) tab 1 mg and 0.5 mg – amended Special Authority criteria  Zoledronic acid (Aclasta) soln for infusion 5 mg in 100 ml – amended Special Authority criteria Increased subsidy Chemical Amoxycillin clavulanate Ketoprofen Tetracosactrin Tiaprofenic acid Presentation Fully subsidised brands

Tab amoxicillin 500 mg with Synermox potassium clavulanate 125 mg Cap long-acting 100 mg and 200 Oruvail SR mg Inj 1 mg per ml, 1 ml Synacthen Depot Tab 300 mg Surgam

A431188

---

Available at www.pharmac.govt.nz/scheduledispatch

Decreased subsidy Chemical Amantadine hydrochloride Anastrozole Presentation Cap 100 mg Tab 1 mg Fully subsidised brands Symmetrel Aremed Arimidex DP-Anastrozole** AFT Arrow-Bendrofluazide Arrow-Bendrofluazide Vannair Partially subsidised brands

Aqueous cream Bendrofluazide

Crm, 500 g Tab 2.5 mg Tab 5 mg Budesonide with Aerosol inhaler 100 μg eformoterol with eformoterol fumarate 6 μg Aerosol inhaler 200 μg with eformoterol fumarate 6 μg Budesonde with Powder for inhalation eformoterol 100 μg with eformoterol fumarate 6 μg Powder for inhalation 200 μg with eformoterol fumarate 6 μg Powder for inhalation 400 μg with eformoterol fumarate 12 μg Cetirizine hydrochloride Tab 10 mg Chlorhexidine gluconate Soln 4% Citalopram hydrobromide Tab 20 mg Compound electrolytes Powder for soln for oral use 5 g Cyproterone acetate with Tab 2 mg with ethinyloestradiol ethinyloestradiol 35 μg and 7 inert tabs Desmopressin Nasal spray 10 μg per dose, 6 ml OP Dextrose Inj 50%, 10 ml Docetaxel Ini 20 mg Inj 80 mg Inj 1 mg for ECP Cap 50 mg Cap 120 mg Tab 100 mg Powder for inhalation, 6 μg per dose, breath activated

Vannair

Symbicort Turbuhaler*

Symbicort Turbuhaler*

Symbicort Turbuhaler*

Zetop Orion Arrow-Citalopram Electral Enerlyte** Ginet 84

Desmopressin-PH&T Biomed Docetaxel Ebewe** Taxotere Docetaxel Ebewe** Taxotere Baxter Laxofast 50 Laxofast 120 Doxine Oxis*

Docusate sodium Doxycycline hydrochloride Eformoterol fumarate

A431188

---

Available at www.pharmac.govt.nz/scheduledispatch

Emulsifying ointment Fentanyl citrate

Oint BP, 500 g Inj 50 μg per ml, 2 ml Inj 50 µg per ml, 10 ml Gliclazide Tab 80 mg Glyceryl trinitrate TDDS 10 mg Hyoscine n-butylbromide Tab 10 mg Ketoconazole Shampoo 2%, 100 ml OP Mesalazine Suppos 500 mg Neostigmine Inj 2.5 mg per ml, 1 ml Nicotinic acid Tab 50 mg Tab 500 mg Nifedipine Tab long-acting 30 mg

AFT Boucher and Muir Boucher and Muir Apo-Gliclazide Nitroderm TTS Gastrosoothe Sebizole

Hospira Hospira

Norfloxacin Omeprazole Pantoprazole Paracetamol Permethrin Pyridostigmine bromide Pyridoxine hydrochloride Ranitidine hydrochloride Ranitidine hydrochloride Simvastatin

Tobramycin Tolcapone Tramadol hydrochloride Triamcinolone acetonide Vancomycin hydrochloride Zopiclone

Asacol AstraZeneca Apo-Nicotinic Acid Apo-Nicotinic Acid Adefin XL Arrow-Nifedipine XR** Tab long-acting 60 mg Adefin XL Arrow-Nifedipine XR** Tab 400 mg Arrow-Norfloxacin Inj 40 mg Dr Reddy’s Omeprazole Inj 40 mg Pantocid IV Oral liq 250 mg per 5 ml Paracare Double Strength 1,000 ml Lotn 5 %, 30 ml OP A-Scabies Tab 60 mg Mestinon Tab 50 mg Apo-Pyridoxine Oral liq 150 mg per 10 Peptisoothe ml Tab 150 mg Arrow-Ranitidine Tab 300 mg Arrow-Ranitidine Tab 10 mg Arrow-Simva 10mg Tab 20 mg Arrow-Simva 20mg Tab 40 mg Arrow-Simva 40mg Tab 80 mg Arrow-Simva 80mg Inj 40 mg per ml, 2 ml DBL Tobramycin Tab 100 mg Tasmar Cap 50 mg Arrow-Tramadol 0.1% in Dental Paste Oracort USP Inj 500 mg Mylan Tab 7.5 mg Apo-Zopiclone

Adalat Oros Adalat Oros

* Higher subsidy by endorsement ** Price and subsidy change on this brand only NB. For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: www.pharmac.govt.nz/healthpros/Schedule.

A431188